Electric Literature of 214894-89-0, Catalysts allow a reaction to proceed via a pathway that has a lower activation energy than the uncatalyzed reaction. In heterogeneous catalysis, catalysts provide a surface to which reactants bind in a process of adsorption.In a document type is Patent, and a compound is mentioned, 214894-89-0, Name is 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine, introducing its new discovery.
A RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE, THE USE OF THE RADIOLABELLED COMPOUND IN A DIAGNOSTIC METHOD OF POSITRON EMISSION TOMOGRAPHY, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE RADIOLABELLED COMPOUND OF QUATERNARY AMMONIUM SALT OF A POLYCYCLIC AROMATIC AMINE
The invention relates to a radioisotope-labelled compound of quaternary ammonium salt of a polycyclic aromatic amine with formula I, wherein the wavy line indicates a single bond between the non-nodal carbon atom of a polycyclic aromatic system and the R1 substituent. In formula I, R1 substituent is independently selected from hydrogen, halogens, a hydroxy optionally protected, C1-4alkoxy, a nitro group, an amino group optionally having 1 or 2 hydrogen atoms replaced with C1-6alkyl or having 2 atoms of hydrogen replaced with C2-5alkylene to form a heterocyclic ring, a chain C1-6carbon group optionally having a halogen, carboxy, formyl or C1-4alkanesulfonic substituent, and a phenyl group optionally having 1-5 substituents independently selected from halogens, a chain C1-6carbon, a halogenated chain Cl-6carbon substituent, a hydroxy optionally protected, C1-4alkoxy, an amino group optionally having 1-2 atoms of hydrogen replaced with C1-6alkyl; R2 is a chain aliphatic substituent having the-CH2- fragment as the terminal member of the chain, to which chain a phenyl group is optionally attached optionally having 1-3 substituents selected from halogens and C1-6alkyl, and, if the chain contains at least 2 carbon atoms, in which chain there is optionally a bivalent link between the carbon atoms, said link selected from the oxygen atom -O-, sulfur atom -S- and C3-6cycloalkylene, wherein the R2 substituent contains a total of 1-16 carbon atoms, and the hydrogen atom at one of the carbon atoms is replaced with an atom of 18F fluorine radioisotope; R3 and R4 are combined to form a bivalent butadienyl-1,3 substituent whose terminal carbon atoms are linked to the adjacent non-nodal carbon atoms of the B ring to form an aromatic C ring fused with the A and B ring system having R1 substituents at non-nodal carbon atoms; n is an integer of 9; X- is a pharmaceutically acceptable counterion, which is an anion of a mono-basic inorganic acid, a mononegative anion of a multi-basic inorganic acid, an anion of an alkanecarboxylic acid, an anion of an aliphatic sulfonic acid, an anion of an aromatic sulfonic acid, an anion of an acidic amino acid; as well as a hydrate or solvate thereof. The invention also relates to the use of the compound according to the invention and a pharmaceutical composition comprising the compound according to the invention.
Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Electric Literature of 214894-89-0. In my other articles, you can also check out more blogs about 214894-89-0